GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » Locust Walk Acquisition Corp (NAS:LWACW) » Definitions » Loans Receivable

LWACW (Locust Walk Acquisition) Loans Receivable : $0.00 Mil (As of Oct. 2020)


View and export this data going back to 2021. Start your Free Trial

What is Locust Walk Acquisition Loans Receivable?

Locust Walk Acquisition's Loans Receivable for the quarter that ended in Oct. 2020 was $0.00 Mil.

Locust Walk Acquisition Loans Receivable Historical Data

The historical data trend for Locust Walk Acquisition's Loans Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Locust Walk Acquisition Loans Receivable Chart

Locust Walk Acquisition Annual Data
Trend
Loans Receivable

Locust Walk Acquisition Semi-Annual Data
Oct20
Loans Receivable -

Locust Walk Acquisition Loans Receivable Calculation

Loans Receivable are the funds that a company has lent but have not yet been repaid.

Locust Walk Acquisition Loans Receivable Related Terms

Thank you for viewing the detailed overview of Locust Walk Acquisition's Loans Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.

Locust Walk Acquisition Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » Locust Walk Acquisition Corp (NAS:LWACW) » Definitions » Loans Receivable
Comparable Companies
Traded in Other Exchanges
N/A
Address
200 Clarendon Street, 51st Floor, Boston, MA, USA, 02116
Website
https://www.locustwalkacquisitioncorp.com
Locust Walk Acquisition Corp is a blank check company.

Locust Walk Acquisition Headlines

From GuruFocus

eFFECTOR Therapeutics Debuts as Publicly Traded Next-Generation Oncology Company Advancing Mature Pipeline with New Class of Cancer Therapies

By Marketwired Marketwired • 08-26-2021

Locust Walk Acquisition Corp. Announces Completion of $175,000,000 Initial Public Offering, Including Exercise of Over-Allotment Option

By PRNewswire PRNewswire • 01-13-2021

eFFECTOR Therapeutics Doses First Patient with COVID-19 in Phase 1b Clinical Trial Evaluating Zotatifin as a Host-Targeted Antiviral Agent

By Marketwired Marketwired • 07-22-2021

Locust Walk Acquisition Corp. Class A Common Shares and Warrants to Commence Trading Separately on March 1, 2021

By PRNewswire PRNewswire • 02-23-2021

eFFECTOR Therapeutics and Locust Walk Acquisition Corp. Announce Merger Agreement to Create Publicly Listed, Next-Generation Oncology Company Developing New Class of Cancer Therapies

By Marketwired Marketwired • 05-27-2021

Locust Walk Acquisition Corp.'s Stockholders Approve Business Combination with eFFECTOR Therapeutics to Create Next-Generation Oncology Company Developing New Class of Cancer Therapies

By Marketwired Marketwired • 08-24-2021

Locust Walk Acquisition Corp. Receives Notification of Deficiency from Nasdaq Related to Delayed Filing of Quarterly Report on Form 10-Q Stemming from SEC Guidance Concerning Balance Sheet Treatment of Warrants

By Marketwired Marketwired • 06-03-2021

eFFECTOR Therapeutics Announces Publication of Tomivosertib Preclinical Data in Cell Reports

By Marketwired Marketwired • 07-16-2021